VBI Vaccines Inc (VBIV) is scheduled to report 2nd quarter earnings on 08/09/2023.
Regarding Q2 estimates, Wall Street analysts expect VBI Vaccines Inc to post earnings of -$2.16 per share. Revenue expectations are pegged at $929 thousand. Last quarter, VBI Vaccines Inc missed earnings estimates, reporting EPS of -$2.43 on estimates of -$2.27. The stock rose by 3.34% the day after the last earnings release.
Year-to-date, VBIV stock has fallen by -89.00%.
About VBI Vaccines Inc
VBI Vaccines, Inc. is a biopharmaceutical company. It engages in the development of eVLP vaccine platform for the design of (e) virus-like-particle vaccines that closely mimic the target virus. The company also involves in the development of thermostable technology that enables the development of vaccines and biologics that can withstand storage or shipment at constantly fluctuating temperatures. VBI Vaccines was founded on July 25, 2014 and is headquartered in Cambridge, MA.
Stay up-to-date on earnings this week, with TipRanks’ Earnings Calendar.
